Filing Analysis
Myomo, Inc. has appointed Joseph M. Manko Jr. to its Board of Directors as a Class I director, effective May 9, 2026. Mr. Manko is the Senior Principal of Horton Capital Management, a significant shareholder in the company, and brings extensive med-tech and investment banking experience.
📋 Key Facts
- Joseph M. Manko Jr. was appointed to the Board of Directors effective May 9, 2026.
- Mr. Manko is the Senior Principal of Horton Capital Management LLC, which is identified as a significant shareholder in the Company.
- He will serve as a Class I director with a term expiring at the 2027 annual meeting of shareholders.
- Non-employee director compensation includes an annual cash retainer of $60,000 and an annual grant of restricted stock units (RSUs) with a grant date fair value of $85,000.
- Mr. Manko currently serves as Chairman of Safeguard Scientifics, Inc. and as a director of KORU Medical Systems, Inc.
Myomo, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were furnished via a press release as part of a routine quarterly earnings disclosure.
📋 Key Facts
- The report was filed on May 7, 2026.
- The financial results cover the first quarter ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the full financial details was furnished as Exhibit 99.1.
Myomo, Inc. has appointed William J. Febbo to its Board of Directors as a Class II director, effective April 14, 2026. Mr. Febbo, the former CEO of OptimizeRx Corporation, brings extensive experience in healthcare technology and capital markets to the board.
📋 Key Facts
- William J. Febbo appointed as a Class II director with a term expiring at the 2028 annual meeting.
- Mr. Febbo served as CEO of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024.
- Compensation includes an initial grant of 45,000 restricted stock units (RSUs) vesting in one year.
- Annual compensation consists of a $60,000 cash retainer and $85,000 in RSUs vesting quarterly.
- Mr. Febbo currently serves as CEO of Performance Health Systems as of February 2026.
Myomo, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, via a press release furnished with the SEC.
📋 Key Facts
- The report was filed on March 9, 2026, covering the period ending December 31, 2025.
- The filing includes Item 2.02 for Results of Operations and Financial Condition.
- Financial data was furnished as Exhibit 99.1 and is not deemed 'filed' for Section 18 liability purposes.
- The company is listed on the NYSE American under the ticker MYO.